WELCOME TO ACOUNS LABORATORY
- Approved testing center for sea and air travel
- No premium added fee for home collection services
- Fast turnaround time: 24-48 hours
- Expertly trained staff
- Home collection of samples by Our skilled trained laboratory scientist
- PCR COVID-19 Testing for pre-employment, personal and travel
Get in touch
Register your details
- At least once, when you are 13 to 64 years old<
- When you think you may have been exposed to the virus
- Before becoming pregnant or when pregnant
- Once a year if you are at increased risk of being exposed to the virus
To reduce the risk of infection or spread of COVID-19, members of the public are advised to adhere to the following handand respiratory hygiene measures:
- Wash your hands regularly with soap and water or use an alcohol-based sanitiser if no water and soap is available
- Use non-medical face mask/covering for all persons while in public spaces. The NCDC has published an advisory on the use of face cloth masks
- Practice no-touch greetings
- Maintain at least 2 metres (6 feet) physical distance between yourself and anyone who is coughing or sneezing
- spaces such as open markets, crowded supermarkets and pharmacies
- Adhere to national and state directives
Shivering /shaking (chills)
Recent loss of taste or smell
Difficulty in breathing/shortness of breath
Hepatitis is an inflammation of the liver that can cause a range of health problems and can be fatal. There are five main strains of the hepatitis virus, referred to as types A, B, C, D and E. While they all cause liver disease, they differ in important ways including modes of transmission, severity of the illness, geographical distribution and prevention methods. In particular, types B and C lead to chronic disease in hundreds of millions of people and, together, are the most common cause of liver cirrhosis, cancer and viral hepatitis-related deaths. An estimated 325 million people worldwide live with hepatitis B and/or C, and for most, testing and treatment remains beyond reach.
Some types of hepatitis are preventable through vaccination. A WHO study found that an estimated 4.5 million premature deaths could be prevented in low- and middle-income countries by 2030 through vaccination, diagnostic tests, medicines and education campaigns. WHO’s global hepatitis strategy, endorsed by all WHO
Member States, aims to reduce new hepatitis infections by 90% and deaths by 65% between 2016 and 2030.
Symptoms of Hepatitis
Many people with hepatitis A, B, C, D or E exhibit only mild symptoms or no symptoms at all. Each form of the virus, however, can cause more severe symptoms. Symptoms of hepatitis A, B and C may include fever, malaise, loss of appetite, diarrhoea, nausea, abdominal discomfort, dark-coloured urine and jaundice (a yellowing of the skin and whites of the eyes). In some cases, the virus can also cause a chronic liver infection that can later develop into cirrhosis (a scarring of the liver) or liver cancer. These patients are at risk of death.
Hepatitis D (HDV) is only found in people already infected with hepatitis B (HBV); however, the dual infection of HBV and HDV can cause a more serious infection and poorer health outcomes, including accelerated progression to cirrhosis. Development of chronic hepatitis D is rare.
Hepatitis E (HEV) begins with mild fever, reduced appetite, nausea and vomiting lasting for a few days. Some persons may also have abdominal pain, itching (without skin lesions), skin rash or joint pain. They may also exhibit jaundice, with dark urine and pale stools, and a slightly enlarged, tender liver (hepatomegaly), or occasionally acute liver failure.
Treatment of Hepatitis
Safe and effective vaccines are available to prevent hepatitis B virus (HBV). This vaccine also prevents the development of hepatitis Dvirus (HDV) and given at birth strongly reduces transmission risk from mother to child. Chronic hepatitis B infection can be treated withantiviral agents. Treatment can slow the progression of cirrhosis, reduce incidence of liver cancer and improve long term survival. Only aproportion of people with chronic hepatitis B infection will require treatment. A vaccine also exists to prevent infections of hepatitis E(HEV), although it is not currently widely available. There are no specific treatments for HBV and HEV and hospitalization is not usuallyrequired. It is advised to avoid unnecessary medications due to the negative effect on liver function caused by these infections.
Hepatitis C (HCV) can cause both acute and chronic infection. Some people recover on their own, while others develop a life-threateninginfection or further complications, including cirrhosis or cancer. There is no vaccine for hepatitis C. Antiviral medicines can cure morethan 95% of persons with hepatitis C infection, thereby reducing the risk of death from cirrhosis and liver cancer, but access to diagnosisand treatment remains low.
Hepatitis A virus (HAV) is most common is low- and middle-income countries due to reduced access to clean and reliable water sourcesand the increased risk of contaminated food. A safe and effective vaccine is available to prevent hepatitis A. Most HAV infections aremild, with the majority of people recovering fully and developing immunity to further infection. However, these infections can also rarelybe severe and life threatening due to the risk of liver failure.